Enantiospecific, selective cyclooxygenase-2 inhibitors

Kevin R Kozak; Jeffery J Prusakiewicz; Scott W Rowlinson; Lawrence J Marnett

doi:10.1016/s0960-894x(02)00133-6

Enantiospecific, selective cyclooxygenase-2 inhibitors

Bioorg Med Chem Lett. 2002 May 6;12(9):1315-8. doi: 10.1016/s0960-894x(02)00133-6.

Authors

Kevin R Kozak¹, Jeffery J Prusakiewicz, Scott W Rowlinson, Lawrence J Marnett

Affiliation

¹ Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

PMID: 11965379
DOI: 10.1016/s0960-894x(02)00133-6

Abstract

Cyclooxygenase inhibition studies with novel indomethacin alkanolamides demonstrate the potential for dramatic differences in inhibitor properties conferred by subtle structural modifications. The transformation of non-selective alpha-(S)-substituted indomethacin ethanolamides to potent, COX-2 selective inhibitors by simple stereocenter inversion highlights this property.

MeSH terms

Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / metabolism
Cyclooxygenase Inhibitors / pharmacology*
Isoenzymes / drug effects*
Isoenzymes / metabolism
Prostaglandin-Endoperoxide Synthases / drug effects*
Prostaglandin-Endoperoxide Synthases / metabolism
Stereoisomerism

Substances

Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases